Compare GSK plc (GSK) vs Seagate Technology Holdings PLC (STX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Seagate Technology Holdings PLC — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Seagate Technology Holdings PLC trades at $783 (market cap $176.19B). The key difference: Seagate Technology Holdings PLC is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Seagate Technology Holdings PLC for 41 Days on average.
| GSK | STX | |
|---|---|---|
Market Cap | $91.88B | $176.19B |
Volume | 7,730,529 | 5,061,875 |
Sector | Health | Technology |
52-Week High | $61.18 | $1.09K |
52-Week Low | $43.24 | $211.63 |
Typical Hold Time | 93 Days | 41 Days |
Enterprise Value | $111.88B | $178.34B |
Dividend Yield | 3.9% | 0.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
STX trades at $783, down 3.01% amid concerns about increased competition from Toshiba's planned HDD production expansion. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $5.71 vs. $5.10, and robust profitability metrics including 26.11% net income margin. Technical indicators are bearish with price near pivot point support at $782, while analyst consensus remains positive with 54% buy ratings and $1,130 price target.
Despite near-term competitive pressures, STX maintains strong AI-driven storage demand positioning. Investment opportunity lies in the company's record margins and nearly sold-out capacity, though risks include potential pricing pressure from increased industry supply and high valuation multiples that may limit upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →
